Brayden D, Creed E, O'Connell A, Leipold H, Agarwal R, Leone-Bay A
Elan Pharmaceutical Technologies, Trinity College, Dublin, Ireland.
Pharm Res. 1997 Dec;14(12):1772-9. doi: 10.1023/a:1012192115828.
The effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) on heparin intestinal absorption were studied using rat in situ ileal and colonic instillations and Caco-2 monolayers.
The flux of heparin was tested in the following groups: i) heparin alone, ii) heparin in the presence of SNAC, iii) heparin in the presence of propylene glycol (PG), and iv) heparin in the presence of SNAC and PG. Heparin absorption was measured by the APTT assay in the in situ models and by the anti-Factor Xa assay in Caco-2. SNAC and [3H]-SNAC fluxes were assessed by HPLC and by scintillation counting respectively.
In the rat ileal and colonic in situ instillations SNAC (17-35 mg) promoted heparin absorption in the presence and absence of PG without damaging the tissue. PG alone did not alter heparin absorption in situ, but it amplified the effect of SNAC. In Caco-2, enhanced heparin fluxes were variable in the presence of non-cytotoxic concentrations of SNAC (< 10 mg/ml) and these effects could not be discriminated from those of PG. Papp values for SNAC alone were 2.2 x 10(-5) cm/s and 2.0 x 10(-5) cm/s in the mucosal-to-serosal and serosal-to-mucosal directions respectively, suggesting a substantial passive transcellular flux. Transport of SNAC was significantly reduced in the presence of heparin and/or PG, perhaps indicating physical association between the agents.
SNAC augmented heparin absorption alone and in combination with PG in the rat in situ models without causing toxicity. Caco-2 had limitations for testing increased heparin absorption due to cytotoxic effects of high concentrations of SNAC and PG. However, SNAC itself was well absorbed across Caco-2 and its mechanism of permeation was determined.
采用大鼠原位回肠和结肠灌注以及Caco-2单层细胞模型,研究N-[8-(2-羟基苯甲酰基)氨基]辛酸钠(SNAC)对肝素肠道吸收的影响。
在以下几组中测试肝素的通量:i)单独肝素组;ii)存在SNAC时的肝素组;iii)存在丙二醇(PG)时的肝素组;iv)存在SNAC和PG时的肝素组。在原位模型中通过活化部分凝血活酶时间(APTT)测定法测量肝素吸收,在Caco-2细胞中通过抗Xa因子测定法测量肝素吸收。分别通过高效液相色谱法(HPLC)和闪烁计数法评估SNAC和[3H]-SNAC的通量。
在大鼠回肠和结肠原位灌注实验中,SNAC(17 - 35 mg)在有或无PG存在的情况下均能促进肝素吸收,且不损伤组织。单独的PG不会改变原位肝素吸收,但会增强SNAC的作用。在Caco-2细胞中,在非细胞毒性浓度的SNAC(< 10 mg/ml)存在时,肝素通量增加情况不一,且这些作用与PG的作用难以区分。单独的SNAC在黏膜到浆膜和浆膜到黏膜方向的表观渗透系数(Papp)值分别为2.2×10⁻⁵ cm/s和2.0×10⁻⁵ cm/s,表明存在大量被动跨细胞通量。在存在肝素和/或PG的情况下,SNAC的转运显著降低,这可能表明这些物质之间存在物理结合。
在大鼠原位模型中,SNAC单独或与PG联合使用均可增加肝素吸收且无毒性。由于高浓度SNAC和PG的细胞毒性作用,Caco-2细胞模型在测试肝素吸收增加方面存在局限性。然而,SNAC本身能够很好地透过Caco-2细胞,并且其渗透机制已被确定。